CAR-T cell therapy debate: the future of lymphoma treatment?
Venetoclax in combination with low-dose cytarabine – a promising regimen for the treatment of AML
What is the role of inotuzumab ozogamicin in ALL
Advances in low grade lymphoma over the past 40 years
Making an IMPACT in ALL therapy: how can cure rates be improved?